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Abstract
Introduction
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common rea-
son for presentation to emergency departments (ED), but the management of these epi-
sodes is often heterogeneous regardless of their potential impact on short-term adverse
outcomes.
Methods
This was a longitudinal, retrospective study of all patients >40 years old admitted to the ED
of two Spanish teaching hospitals for an AECOPD between January 1st and May 31st, 2016.
All data were collected from electronic medical records. The primary outcomes were patient
treatment at discharge and 90-day mortality. Logistic regression was used to model the
determinants of 90-day mortality.
Results
Of the 465 included patients, 56% were prescribed a 3-drug combination at hospital discharge,
22% a 2-drug combination, 19% a single drug, and 4% other or no treatment. Approximately
8% of patients died within 90 days after an AECOPD. Multivariate logistic models revealed that
having more than 2 severe exacerbations within the last 12 months (OR (95% CI): 15.12
(4.22–54.22)) and being prescribed a single drug at discharge (OR (95% CI): 7.23 (2.44–
21.38)) were the main determinants of 90-day mortality after an AECOPD.
Conclusions
This study reflects the real-life heterogeneity in the pharmacological treatments prescribed
after an ED admission for an AECOPD and suggests the potential impact of suboptimal
inhaled treatment strategies on 90-day mortality rates.
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Introduction
An acute exacerbation of chronic obstructive pulmonary disease (COPD; AECOPD) is an epi-
sode of worsening of the patient’s respiratory symptoms (i.e., baseline dyspnea, cough, and/or
sputum production) beyond the normal day-to-day variation that are sufficient to warrant a
change in medication [1]. An AECOPD is the most relevant event affecting COPD mortality
and, in fact, the frequency and severity of these episodes are the major modifiers the manage-
ment and outcome of the disease [2]. COPD, particularly AECOPD, accounts for significant
consumption of health care resources [3]. In Spain, AECOPD accounts for 1%-2% of all emer-
gency department (ED) visits, and up to 10% of all medical admissions are related to COPD
[4]; similar data have been reported elsewhere [5]. Moreover, it is estimated that one out of ten
patients suffering from an AECOPD requiring in-hospital management die during the follow-
ing 90 days [6]. Thus, AECOPD can be considered a major public health issue.
International guidelines support the use of inhaled bronchodilators as the cornerstone of
management of COPD, and it is well known how these medications contribute to improving
patient symptoms and quality of life [7]. Moreover, there is enough evidence that supports the
use of inhaled bronchodilators in the prevention of disease progression and relapsing exacer-
bations [8]. However, unlike many other factors that have been associated with mortality [9],
the influence of maintenance inhaled treatment on short-term prognosis after an acute exacer-
bation has not been elucidated yet. In this sense, understanding whether a particular broncho-
dilator or inhaled glucocorticoid treatment, used either alone or in combination, after an
AECOPD can influence mortality may be very relevant not only because of the potential effects
of these medications at the respiratory level but also because of their effects on the inflamma-
tory response and their potential to reduce the risk of death due to cardiovascular causes [10].
In this scenario, we conducted a retrospective longitudinal study to assess clinical predictors of
short-term adverse outcomes, including mortality, of different strategies of maintenance treat-
ment prescribed at hospital discharge after an ED visit because of an AECOPD.
Methods
Study design and subjects
This was a longitudinal, retrospective study of the first 500 patients >40 years old admitted to
the EDs of two Spanish hospitals because of an AECOPD (primary cause according to usual
practice in the participating EDs) from January 1st to May 31st, 2016. The participating centers
were Arnau de Vilanova University Hospital (HUAV), in Lleida, and Bellvitge University Hos-
pital (HUB), in Barcelona; both of them are regional reference hospitals. To be included in the
current analyses, all patients had to have spirometric confirmation of COPD, according to
international guidelines, or a previous diagnosis of COPD with specific treatment and follow-
up with a primary care (PC) or secondary care (SC) physician. In the latter case, inclusion in
the study required the confirmation of the case by a senior physician based on the information
available in the electronic medical records. This confirmation was performed at the time of
data collection, thus months after the ED admission.
Patients were excluded if they had any other identifiable cause of the worsening of their
symptoms (pneumonia, pneumothorax, decompensated or unknown arrhythmia, ischemic
heart disease, pulmonary thromboembolism or left heart failure); if they required invasive
mechanical ventilation at the time of the first medical visit (as these patients are directly
referred to the intensive care unit); or if they received ambulatory follow-up in a palliative care
unit. Patients with more than one exacerbation requiring an ED visit during the study period
were considered only once.
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Clinical data and measurements. Based on the data available in the electronic medical
records of each patient, the following variables were collected: sociodemographic and lifestyle
data (age, sex, smoking status and alcohol consumption); comorbidities (age-modified Charl-
son index [11]); baseline characteristics of COPD (degree of obstruction, basal dyspnea, his-
tory of exacerbations during the last 12 months, “clinical phenotype” according to the Spanish
national guidelines [12], and Global Initiative for Chronic Obstructive Lung Disease (GOLD)
2017 ABCD classification [7]); pharmacological treatment before and after ED admission;
overall characteristics of the AECOPD in the ED (amount of time since the onset of symptoms,
Anthonisen criteria, vital signs, pulse oxygen saturation, fraction of inspired oxygen, and any
complementary tests); and variables related to the hospital admission (length of stay and in-
hospital mortality). Any stay longer than 24 h in any hospital ward, unit or ED was considered
a hospital admission. Finally, all participants were retrospectively followed for 90 days after
discharge from the hospital or ED and the following information was collected from the pri-
mary care electronic medical records (ECAP): time to first PC assessment after the AECOPD;
number of readmissions at 90 days; and mortality at 90 days.
The following pharmacological treatments for COPD were considered: short-acting beta ago-
nists (SABA); long-acting beta agonists (LABA); short-acting muscarinic antagonists (SAMA);
long-acting muscarinic antagonists (LAMA); inhaled corticosteroids (ICS); and other drugs
(inhaled antibiotics, oral antibiotics, roflumilast, theophylline and n-acetylcysteine). However, the
use of short-acting bronchodilators was ignored when these medications were prescribed as res-
cue or relief drugs only, and not as part of maintenance treatment. Pharmacological treatments
were considered both individually and grouped as 3-drug, 2-drug or single-drug treatments, this
reflecting treatment intensity. The 3-drug combinations included: LAMA + LABA + ICS; LAMA
+ SABA + ICS; and, LABA + SAMA + ICS. The 2-drug combinations included: LAMA + LABA;
LAMA + SABA; LAMA + ICS; LABA + SAMA; LABA + ICS; and, SAMA or SABA + ICS. When
considering drug combinations, the combination of LAMA + SAMA was considered as LAMA
alone; the combination of LABA + SABA was considered as LABA alone; and, inhaled antibiotics,
oral antibiotics, roflumilast, theophylline and n-acetylcysteine were grouped into the “other treat-
ment” category and were not considered in the 3-drug, 2-drug or single-drug categories.
All data were collected by medical research staff and entered into an anonymized database.
The ethics committee of the coordinator center (HUAV) approved the study (approval num-
ber 10/2015).
Statistical analysis. Baseline characteristics of included patients were described using the
mean (standard deviation [SD]) or median (P25-P75) for continuous variables and absolute
numbers and percentages for categorical variables. Bivariate analysis according to survival sta-
tus at 90 days were performed using the Chi-square test, Student’s t-test, or the Mann-Whitney
U test, depending on the characteristics of each variable. Logistic regression was used to model
the determinants of 90-day mortality. A multivariate model including all variables that were
statistically significant in the univariate models as well as age, gender, tobacco use and whether
the patient required hospital admission was constructed. Additionally, stratified analyses
according to gender and center were performed. All comparisons were bilateral, and a value of
p<0.05 was considered statistically significant. All analyses were performed using Stata 12.1
software (StataCorp, College Station, TX, USA).
Results
Patient characteristics
The first 500 patients who presented with an AECOPD from January 1st to May 31st, 2016,
were considered for this analysis; 250 patients at the ED of HUAV and 250 at the ED of HUB
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were evaluated. Thirty-five patients were excluded (12 because they had spirometric values
incompatible with the diagnosis of COPD, and 23 were excluded because they had a non-
COPD diagnosis as the predominant cause of respiratory disease). Therefore, the study con-
sisted of a sample of 465 patients: 217 (47%) from HUAV and 248 (53%) from HUB. Table 1
shows the main characteristics of the study population. Briefly, included patients had a mean
(SD) age of 75 (11) years with an average modified Charlson index of 6.5 (2.1); spirometry was
available in 81.5% of patients, with an average forced expiratory volume in the 1st second
(FEV1) of 50.5% (20.3%) of the predicted value; persistent dyspnea, which was defined as a
score of 2 or more on the modified Medical Research Council (mMRC) dyspnea scale, was
present in 80% of patients; 69% of patients were graded as C-D according to the GOLD 2017
ABCD classification; and approximately 58% of patients required hospital admission. No rele-
vant differences in baseline characteristics and patient outcomes were found between the two
hospitals.
Table 2 shows the pharmacological treatments before ED admission and at discharge from
the ED or at discharge from the hospital, if admission was required. Briefly, approximately
56% of patients were prescribed a 3-drug combination at hospital discharge, 22% a 2-drug
combination, 19% a single drug, and 4% other or no treatment. Approximately 74% of patients
were discharged without any changes in their baseline treatment, and only 20% of patients had
an increase in the intensity of their treatment with the addition of inhaled drugs from a differ-
ent class of medications.
Table 3 describes the relationship between the treatment at discharge and survival status at
90 days after discharge. The lowest mortality rates (5%) were found among patients receiving a
3-drug combination, while the highest (15%) were found among patients receiving a single-
drug treatment. The main determinants of mortality during the 90 days following an AECOPD
are shown in Table 4. Briefly, crude analyses showed that treatment, age, past severe exacerba-
tions and age-modified Charlson index were positively associated with an increased mortality
risk. Adjusted analyses confirmed that treatment and previous severe exacerbations were the
main determinants of 90-day mortality. The number of combined treatments was significantly
associated with a lower 90-day mortality (p-for-trend = 0.002). The effect of variables such as
age or a requirement for hospital admission during an AECOPD did not reach statistical sig-
nificance in the adjusted models. Finally, sensitivity analyses excluding patients without a spi-
rometric confirmation of COPD showed similar results (S1 Additional Results).
Discussion
This study highlights the heterogeneity in the pharmacological treatments prescribed after an
ED admission because of an AECOPD and the relationship of these different treatments to
90-day mortality. As expected, patients with a previous history of repeated severe COPD exac-
erbations showed an increased risk of short-term mortality after an AECOPD. However, in
this real-world population, the pharmacological strategy of inhaled treatments prescribed at
discharge from the hospital or the ED was found to have a significant impact on 90-day mor-
tality rates. Specifically, low-intensity treatments, defined as the use of a single maintenance
drug, were associated with higher mortality rates than 3-drug combination treatments, regard-
less of the severity of the AECOPD. This study also revealed that the global therapeutic
approach for high-risk patients with COPD after presenting to the hospital with an AECOPD
did not always correspond to the recommendations based on the best available scientific
evidence.
There is currently enough evidence that supports the use of pharmacological therapy for
COPD to reduce symptoms, reduce the frequency and severity of exacerbations and increase
Treatment strategies and mortality in COPD
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Table 1. Main characteristics of the study population.
n� n (%)/mean (SD)/P50 (P25-P75)
Sociodemographic variables
Age, years 465 75.2 (11.2)
Sex 465
Men 372 (80%)
Women 93 (20%)
Center 465
Lleida 217 (47%)
Bellvitge 248 (53%)
Lifestyle and comorbidities
Tobacco use: 450
Never 64 (14%)
Current 95 (21%)
Former 291 (65%)
Alcohol, units of alcohol/day 385 0 (0–2)
Age-modified Charlson index 464 6.5 (2.1)
Vaccination: Influenza 465 424 (91%)
Vaccination: PNC23 465 319 (69%)
Vaccination: Prevenar 13 465 57 (12%)
Baseline COPD variables
Clinical phenotype 449
Non-exacerbator 52 (12%)
Exacerbator emphysema 112 (25%)
Exacerbator chronic bronchitis 211 (47%)
Asthma-COPD overlap 74 (16%)
GOLD 2017 ABCD classification 438
A 123 (28%)
B 11 (3%)
C 225 (51%)
D 79 (18%)
Bronchiectasis 442 122 (28%)
Dyspnea, mMRC scale 459
0/1 89 (20%)
2 276 (60%)
3 84 (18%)
4 10 (2%)
FVC, % predicted 377 66.8 (21.6)
FEV1, % predicted 378 50.5 (20.3)
FEV1/FVC, % 379 55.6 (14.8)
Mild/moderate exacerbations in the last 12 months 458 2 (1–3)
Severe exacerbations in the last 12 months 440 0 (0–1)
Case evaluation
Length of stay in the ED, h 465 9.4 (6.0)
Required hospital admission 465 270 (58%)
Ward/department during hospitalization 270
Unspecified ward 63 (23%)
Respiratory department 60 (22%)
Internal medicine 110 (41%)
(Continued)
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Table 1. (Continued)
n� n (%)/mean (SD)/P50 (P25-P75)
Geriatrics 35 (13%)
Home hospitalization 2 (1%)
Length of stay in the hospital, days 270 6.9 (4.7)
AECOPD outcome 465
Deceased in the ED 6 (1%)
Deceased during hospitalization 16 (4%)
Discharged 443 (95%)
Rehospitalization at 90 days 440 108 (25%)
Deceased at 90 days 443 33 (8%)
PNC23: 23-valent pneumococcal polysaccharide vaccine; mMRC: modified Medical Research Council; FVC: forced
vital capacity; FEV1: forced expiratory volume in the 1
st second; ED: emergency department; and AECOPD: acute
exacerbation of chronic obstructive pulmonary disease.
� Subjects with available information (no missing information) from a total of 465 subjects in the study.
https://doi.org/10.1371/journal.pone.0208847.t001
Table 2. Pharmacological treatment before ED admission and at hospital discharge.
Previous treatment Treatment at discharge
Treatment combinations
LAMA + LABA + ICS 93 (20%) 80 (18%)
LAMA + SABA + ICS 0 (0%) 1 (0%)
LABA + SAMA + ICS 139 (30%) 166 (38%)
LAMA + LABA 31 (7%) 39 (9%)
LAMA + SABA 8 (2%) 8 (2%)
LAMA + ICS 6 (1%) 4 (1%)
LABA + SAMA 7 (2%) 6 (1%)
LABA + ICS 39 (8%) 29 (7%)
SAMA or SABA + ICS 13 (3%) 12 (3%)
LAMA 26 (6%) 18 (4%)
LABA 6 (1%) 2 (1%)
SABA or SAMA 46 (10%) 59 (13%)
ICS 3 (1%) 3 (1%)
Other� 0 (0%) 8 (2%)
Nothing 48 (10%) 8 (2%)
Categorized treatment combinations
3-drug combination 232 (50%) 247 (56%)
2-drug combination 104 (22%) 98 (22%)
Single drug 81 (18%) 82 (19%)
Other� or nothing 48 (10%) 16 (4%)
LAMA: long-acting muscarinic antagonists; LABA: long-acting beta agonists; ICS: inhaled corticosteroids; SABA:
short-acting beta agonists; and SAMA: short-acting muscarinic antagonists.
� Other drugs: inhaled antibiotics, oral antibiotics, roflumilast, theophylline or n-acetylcysteine.
The combination of LAMA + SAMA was considered LAMA alone; and the combination of LABA + SABA was
considered LABA alone. The use of short-acting bronchodilators was ignored except when these medications were
prescribed as part of maintenance treatment and not only as rescue or relief drugs.
https://doi.org/10.1371/journal.pone.0208847.t002
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exercise tolerance and overall health status [13,14]. However, to date, few studies have assessed
whether bronchodilators or ICS can significantly affect mortality or improve lung function or
whether these effects are a result of these drugs used separately or used in combination in a sin-
gle device [15–18]. A retrospective study of 4,263 patients showed a 42% reduction in the risk
of death or readmission in the year after the first severe AECOPD in patients who received
treatment with LABA/ICS compared to those who received less intensive therapy (ICS, LABA
or SABA) [19]. Gudmunson et al. showed that both LABA and the LABA/ICS combination
were associated with a decrease in the risk of death after a hospital admission due to an
AECOPD [20]. Finally, a retrospective study of 1,185 patients by Sarc et al. found that long-
term mortality after an AECOPD might be related to pharmacological treatment, since non-
survivors were prescribed LABA, ICS and tiotropium less frequently and were prescribed the-
ophylline more frequently [21].
The potential effects of bronchodilators and ICS as well as combinations of these medica-
tions on mortality can be explained by several mechanisms: first, inhaled treatment has been
demonstrated to be a preventive measure against subsequent exacerbations due to its effects
on hyperinflation and mechanical stress, decreased mucus production and enhanced mucocili-
ary clearance [22]; and second, potential anti-inflammatory properties can have a positive
impact on endothelial function and blood pressure, similar to how lung volume reduction sur-
gery in patients with severe COPD reduces cardiovascular mortality [23]. However, our find-
ings may be the result of an inadequate risk assessment by the attending physician, leading to
suboptimal prescription of inhaled treatments. This possibility is supported by a recent big
data analysis performed in Spain that proposed that suboptimal treatment, even in patients
with severe COPD, may persist due to an underestimation of the significance of the disease or
an ignorance about the indications and benefits of different pharmacological treatments [24].
Finally, it can be argued that patients who do not require hospitalization and thus are dis-
charged directly from ED, may be prescribed suboptimal treatments due to the assumption
that choosing the most appropriate medications and providing training with different inhala-
tion devices are the responsibilities of the PC physician. Nevertheless, this argument does not
apply to patients with severe exacerbations requiring hospitalization, who are at elevated risk
of adverse events after discharge from the hospital.
Table 3. Pharmacological treatment at hospital discharge according to survival status at 90-days after an
AECOPD.
Alive Deceased
n (%) n (%) p-value�
Categorized treatment combinations 0.027
3-drug combination 235 (95%) 12 (5%)
2-drug combination 91 (93%) 7 (7%)
Single drug 70 (85%) 12 (15%)
Other�� or nothing 14 (88%) 2 (13%)
� Chi-square test.
�� Other drugs: inhaled antibiotics, oral antibiotics, roflumilast, theophylline or n-acetylcysteine.
The combination of LAMA + SAMA was considered LAMA alone; and the combination of LABA + SABA was
considered LABA alone. The use of short-acting bronchodilators was ignored except when these medications were
prescribed as part of maintenance treatment and not only as rescue or relief drugs.
LAMA: long-acting muscarinic antagonists; LABA: long-acting beta agonists; SABA: short-acting beta agonists; and
SAMA: short-acting muscarinic antagonists.
https://doi.org/10.1371/journal.pone.0208847.t003
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Previous studies investigating risk factors for rehospitalization and death in patients with
severe AECOPD reported similar short-term mortality rates [25–27]. The main determinant
of 90-day mortality in our study was severe exacerbations during the previous 12 months. It is
well known that previous hospitalizations for an AECOPD are independent predictors of
respiratory and all-cause mortality [26,28,29], and each new hospitalization significantly
increases the mortality rate during the subsequent 3 months [30]. Our results are fully aligned
with the previous literature and highlight the relevance of previous severe exacerbations as pre-
dictors of short-term mortality after an AECOPD.
The main strengths of this study are its real-life setting, which reflects the broad range of
combined therapies prescribed that are not always in agreement with the current guidelines,
and its multicenter design, which captures the combined heterogeneity of two different hospi-
tals with different procedures. On the other hand, several limitations should be acknowledged:
(i) The retrospective design implies a degree of missing data, as only the information
Table 4. Main determinants of mortality during the 90 days following an AECOPD.
Crude � Adjusted ��
OR 95% CI OR 95% CI
Categorized treatment combinations:
3-drug combination ref ref
2-drug combination 1.54 0.54–4.37 1.81 0.57–5.73
Single drug 4.43 1.83–10.77 7.23 2.44–21.38
Other��� or nothing 3.35 0.67–16.91 3.31 0.49–22.31
Sex: woman 0.66 0.22–1.95 0.89 0.19–4.16
Age 1.04 1.00–1.08 1.04 0.98–1.10
Center: Bellvitge 0.71 0.33–1.49 0.65 0.27–1.59
Tobacco use:
Never ref ref
Current 1.13 0.26–4.94 1.05 0.15–7.31
Former 1.59 0.46–5.52 0.86 0.16–4.61
Mild/moderate exacerbations in the last 12 months
0 ref ref
1 2.37 0.51–11.01 2.09 0.39–11.09
2 0.78 0.13–4.81 0.63 0.09–4.62
3+ 2.27 0.49–10.44 2.01 0.35–11.59
Severe exacerbations in the last 12 months
0 ref ref
1 1.34 0.48–3.74 1.40 0.45–4.34
2 2.04 0.61–6.71 2.39 0.61–9.33
3+ 9.16 3.40–24.73 15.12 4.22–54.22
Requires hospital admission 1.44 0.66–3.16 1.58 0.59–4.22
Age-modified Charlson index 1.27 1.07–1.50 1.08 0.87–1.36
� A model for each variable (n = 405 in all models).
�� A single model including all variables (n = 405).
��� Other drugs: inhaled antibiotics, oral antibiotics, roflumilast, theophylline or n-acetylcysteine.
The combination of LAMA + SAMA was considered LAMA alone; and the combination of LABA + SABA was
considered LABA alone. The use of Short-acting bronchodilators was ignored except when these medications were
prescribed as part of maintenance treatment and not only as rescue or relief drugs.
AECOPD: acute exacerbation of chronic obstructive pulmonary disease; LAMA: long-acting muscarinic antagonists;
LABA: long-acting beta agonists; SABA: short-acting beta agonists; and SAMA: short-acting muscarinic antagonists.
https://doi.org/10.1371/journal.pone.0208847.t004
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successfully recorded in the ED, hospital and PC records was available. (ii) Up to 19% of
patients did not have spirometric confirmation of COPD, which highlights deficiencies in the
assessment and/or recording of key information of COPD patients. To be included in the cur-
rent analysis, patients without spirometric confirmation of COPD had the diagnosis con-
firmed by a comprehensive review of their medical records, which included a COPD diagnosis
with specific treatment and follow-up with a PC or SC physician, as successfully implemented
in previous studies [9–13, 30]. (iii) No information on patients’ treatment compliance was
available. However, the impact of misclassification that any noncompliant patient might have
on the study results would necessarily cause regression to the null effect and would not influ-
ence any already statistically significant results. (iv) In order to describe the most realistic sce-
nario, patients with asthma-COPD overlap were not excluded from the study, even if these
patients might experience additional benefits from treatment with ICS.
In conclusion, this study reflects the real-life heterogeneity in the pharmacological treat-
ments prescribed after an ED admission for an AECOPD and suggests the potential impact of
suboptimal inhaled treatment strategies on 90-day mortality rates. Specifically, low-intensity
treatment, defined as the use of a single maintenance drug, appeared to be associated with
higher mortality rates than 3-drug combination treatments, regardless of patient severity.
Moreover, we confirmed the key role of previous severe COPD exacerbations as determinants
of 90-day mortality. Overall, we highlighted the importance of appropriate assessment and
treatment of patients suffering from an AECOPD according to the most updated guidelines,
specifically those regarding inhaled therapy.
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S1 Additional Results. Main determinants of mortality during the 90 days following an
AECOPD, excluding patients without a spirometric confirmation of COPD.
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